{"drugs":["Crofelemer","Fulyzaq"],"mono":{"0":{"id":"930357-s-0","title":"Generic Names","mono":"Crofelemer"},"1":{"id":"930357-s-1","title":"Dosing and Indications","sub":[{"id":"930357-s-1-4","title":"Adult Dosing","mono":"<b>HIV infection, receiving anti-retroviral therapy - Non-infective diarrhea:<\/b> 125 mg ORALLY twice daily "},{"id":"930357-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients."},{"id":"930357-s-1-6","title":"Dose Adjustments","mono":"<b>CD4 cell count\/viral load:<\/b> no dose adjustment recommended "},{"id":"930357-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection, receiving anti-retroviral therapy - Non-infective diarrhea<br\/>"}]},"3":{"id":"930357-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930357-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930357-s-3-10","title":"Precautions","mono":"<ul><li>infectious etiology of diarrhea; risk of worsening infection; rule out before initiating therapy<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930357-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930357-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930357-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Flatulence (3.1%)<\/li><li><b>Hepatic:<\/b>Increased bilirubin level (3.1%)<\/li><li><b>Respiratory:<\/b>Bronchitis (3.9%), Cough (3.5%), Upper respiratory infection (5.7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastroenteritis (1% to 2%)<\/li><li><b>Hematologic:<\/b>Decreased white blood cell count (1% to 2%)<\/li><li><b>Immunologic:<\/b>Herpes zoster (1% to 2%)<\/li><li><b>Renal:<\/b>Increased frequency of urination (1% to 2%)<\/li><\/ul>"},"6":{"id":"930357-s-6","title":"Drug Name Info","sub":{"0":{"id":"930357-s-6-17","title":"US Trade Names","mono":"Fulyzaq<br\/>"},"2":{"id":"930357-s-6-19","title":"Class","mono":"Antidiarrheal<br\/>"},"3":{"id":"930357-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930357-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930357-s-7","title":"Mechanism Of Action","mono":"Crofelemer inhibits chloride ion channels that regulate chloride ion and fluid secretion by intestinal epithelial cells, resulting in a blockade of chloride ion secretion and the associated high volume water loss in diarrhea.<br\/>"},"8":{"id":"930357-s-8","title":"Pharmacokinetics","sub":[{"id":"930357-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, oral: minimal<\/li><li>Effects of food: no effect on systemic exposure<\/li><\/ul>"}]},"9":{"id":"930357-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with or without food<\/li><li>swallow whole; do not crush or chew<\/li><\/ul>"},"10":{"id":"930357-s-10","title":"Monitoring","mono":"reduced frequency of loose stools associated with HIV\/AIDs may indicate efficacy<br\/>"},"11":{"id":"930357-s-11","title":"How Supplied","mono":"<b>Fulyzaq<\/b><br\/>Oral Tablet, Delayed Release: 125 MG<br\/>"},"13":{"id":"930357-s-13","title":"Clinical Teaching","mono":"This drug may cause upper respiratory tract infection, bronchitis, cough, or flatulence. <br\/>"}}}